# A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

> **NCT02755649** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 325 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT02755649
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-31
- **Primary completion:** 2017-01-04
- **Final completion:** 2017-03-31
- **Target enrollment:** 325 (ACTUAL)
- **Last updated:** 2020-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02755649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02755649, "A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02755649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*